Application of blend fuels in a diesel engine

AbstractExperimental study has been carried out to analyze engine performance and emissions characteristics for diesel ngine using different blend fuels without any engine modifications. A total of four fuel samples, such as DF (100% iesel fuel), JB5 (5% jatropha biodiesel and 95% DF), JB10 (10% JB and 90% DF) and J5W5 (5% JB, 5% waste ooking oil and 90% DF) respectively were used in this study. Engine performance test was carried out at 100% load eeping throttle 100% wide open with variable speeds of 1500 to 2400rpm at an interval of 100rpm. Whereas, mission tests were carried out at 2300rpm at 100% and 80% throttle position. As results of investigations, the erage torque reduction compared to DF for JB5, JB10 and J5W5 was found as 0.63%, 1.63% and 1.44% and verage power reduction was found as 0.67%, 1.66% and 1.54% respectively. Average increase in bsfc compared to F was observed as 0.54%, 1.0% JB10 and 1.14% for JB5, JB10 and J5W5 respectively. In case of engine exhaust as emissions, compared to DF average reduction in HC for JB5, JB10 and J5W5 at 2300rpm and 100% throttle osition found as 8.96%, 11.25% and 12.50%, whereas, at 2300 and 80% throttle position, reduction was as 16.28%, 0.23% and 31.98% respectively. Average reduction in CO at 2300rpm and 100% throttle position for JB5, JB10 and 5W5 was found as 17.26%, 25.92% and 26.87%, whereas, at 80% throttle position, reduction was observed as 0.70%, 33.24% and 35.57%. Similarly, the reduction in CO2 compared to DF for JB5, JB10 and J5W5 at 2300rpm nd 100% throttle position was as 12.10%, 20.51% and 24.91%, whereas, at 80% throttle position, reductions was bserved as 5.98%, 10.38% and 18.49% respectively. However, some NOx emissions were increased for all blend els compared to DF. In case of noise emission, sound level for all blend fuels was reduced compared to DF. It can e concluded that JB5, JB10 and J5W5 can be used in diesel engines without any engine modifications However, 5B5 produced some better results when compared to JB10

Engine performance and emissions analysis using “Envo Diesel” and coconut biodiesel blended fuel as alternative fuels

The Environmental concerns and regulations to reduce green house gas emission and fluctuation of fossil fuel price have stimulated research on alternative fuels. Moreover, use of unproductive land to produce vegetable oil which is a potential biodiesel source has opened up a way to reduce oil bill. Biodiesel does not need major modification in engine, even though it causes some engine problems in long term use. This paper presents experimental results that evaluates the performance and exhaust emissions of a diesel engine operated on “Envo Diesel” which consists of 5% palm diesel and 95% ordinary diesel fuel (also termed as P5) and C5 (5% coconut biodiesel and 95% ordinary diesel fuel. Experimental results showed that P5 and C5 reduced brake power compared to diesel fuel by 1.2% and 0.7% respectively. Emissions such as HC, smoke, CO and NOx concentration were lesser for P5 and C5. The results of this investigation will be used to partial replacement of diesel fuel using low percentage of methyl ester (maximum 5%) obtained from waste vegetable oils

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Prospects of dedicated biodiesel engine vehicles in Malaysia and Indonesia

Petro diplomacy has played its role in last few decades and that makes energy security a major concern worldwide. Rapid climate change and environmental protection is another vital issue to be addressed in recent energy policies. So an alternative carbon neutral transport fuel is a must in new sustainable energy mix. Biodiesel has immense potentiality to be a part of a sustainable energy mix. In this energy scenario, Brazil's success is a role model in utilizing its agro-industry for reducing poverty, greenhouse gas emission and petro-dependency simultaneously. Brazil commercialized bioethanol in mass scale by introducing flexible fuel vehicles in market. This dedicated engine idea moralizes a new concept of dedicated biodiesel engine vehicles for Malaysia and Indonesia. Southeast Asian countries, i.e. Malaysia and Indonesia is the largest producer as well as exporter of palm oil. Growing at highest yield rate among other biodiesel feedstock, palm based biodiesel is a top exported product for this region. This paper will quantify the prospects of a dedicated biodiesel engine vehicle for Malaysia and Indonesia that will initiate palm based biodiesel in fuel supply chain by leapfrogging the barriers of biodiesel utilization by boosting local automobile industry simultaneously. This article will also review on energy scenario of Malaysia and Indonesia and their renewable energy policies and challenges for coming decades.Palm Biodiesel Biodiesel engine Energy policy Malaysia Indonesia